Systematic review of model-based analyses reporting the cost-effectiveness and cost-utility of cardiovascular disease management programs

Maru, Shoko, Byrnes, Joshua, Whitty, Jennifer A., Carrington, Melinda J., Stewart, Simon and Scuffham, Paul A. (2015) Systematic review of model-based analyses reporting the cost-effectiveness and cost-utility of cardiovascular disease management programs. European Journal of Cardiovascular Nursing, 14 (1). pp. 26-33. ISSN 1474-5151

Full text not available from this repository. (Request a copy)

Abstract

Background: The reported cost effectiveness of cardiovascular disease management programs (CVD-MPs) is highly variable, potentially leading to different funding decisions. This systematic review evaluates published modeled analyses to compare study methods and quality. Methods: Articles were included if an incremental cost-effectiveness ratio (ICER) or cost-utility ratio (ICUR) was reported, it is a multi-component intervention designed to manage or prevent a cardiovascular disease condition, and it addressed all domains specified in the American Heart Association Taxonomy for Disease Management. Nine articles (reporting 10 clinical outcomes) were included. Results: Eight cost-utility and two cost-effectiveness analyses targeted hypertension (n=4), coronary heart disease (n=2), coronary heart disease plus stoke (n=1), heart failure (n=2) and hyperlipidemia (n=1). Study perspectives included the healthcare system (n=5), societal and fund holders (n=1), a third party payer (n=3), or was not explicitly stated (n=1). All analyses were modeled based on interventions of one to two years’ duration. Time horizon ranged from two years (n=1), 10 years (n=1) and lifetime (n=8). Model structures included Markov model (n=8), ‘decision analytic models’ (n=1), or was not explicitly stated (n=1). Considerable variation was observed in clinical and economic assumptions and reporting practices. Of all ICERs/ICURs reported, including those of subgroups (n=16), four were above a US$50,000 acceptability threshold, six were below and six were dominant. Conclusion: The majority of CVD-MPs was reported to have favorable economic outcomes, but 25% were at unacceptably high cost for the outcomes. Use of standardized reporting tools should increase transparency and inform what drives the cost-effectiveness of CVD-MPs.

Item Type: Article
Uncontrolled Keywords: cardiovascular disease,disease management,cost effectiveness,economic evaluation,markov model
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: Pure Connector
Date Deposited: 26 Apr 2016 12:02
Last Modified: 22 Apr 2020 01:19
URI: https://ueaeprints.uea.ac.uk/id/eprint/58385
DOI: 10.1177/1474515114536093

Actions (login required)

View Item View Item